Results 91 to 100 of about 5,730 (206)

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment

Annals of Hepatology, 2017
The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this ...
Alicia Senín, Teresa Broquetas, Sabela Lens, Nuria Cañete, María-Carlota Londoño, Mariana Ferraro, Xavier Forns, Antonio Salar, Jose A. Carrión   +8 more
doaj   +1 more source

Era of direct acting antivirals in chronic hepatitis C: Who will benefit? [PDF]

, 2015
published_or_final_versio
Fung, JYY
core   +1 more source

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients [PDF]

, 2017
Short communication[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and ...
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Meijide, Héctor, Mena, Álvaro, Morano, Luis, Pedreira, José D., Pernas, Berta, Poveda, Eva, Rodríguez-Osorio, Iria, Suárez, Marta, Tabernilla, Andrés   +12 more
core   +2 more sources

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

PLoS ONE, 2017
BackgroundIntracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR).
Valeria Cento, Thi Huyen Tram Nguyen, Domenico Di Carlo, Elisa Biliotti, Laura Gianserra, Ilaria Lenci, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Matteo Bolis, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D'Arminio Monforte, Massimo Andreoni, Antonio Craxì, Mario Angelico, Caterina Pasquazzi, Gloria Taliani, Jeremie Guedj, Carlo Federico Perno, Francesca Ceccherini-Silberstein   +40 more
doaj   +1 more source

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison [PDF]

Additional data on meta-analyses and historical comparisons.
Anne-Kathrin Claes, Frank Andersohn, Jörg Mahlich, Jürgen Kurt Rockstroh, Werner Kulp   +4 more
core   +2 more sources

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens

The Egyptian Journal of Internal Medicine, 2019
Background The recommended reliance on 12 weeks posttreatment sustained virological response (SVR12) instead of SVR24 was validated for treatment evaluation. Aim Judging claimed concordance between SVR12 and SVR24.
Maha M Elsabaawy, Khalid Gameel, Heba Eldemerdash, Talaat Zakareia, Mahmoud Eltahawy, Marry Albert, Marwa Fekry, Enas Ouda, Helmy Elshazly, Ashraf Eljaky   +9 more
doaj   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj  

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Revista do Instituto de Medicina Tropical de São Paulo, 2018
Due to the severity of chronic hepatitis C, there are multiple factors that can negatively affect the quality of life of infected patients. The aim of this study was to evaluate changes in the health-related quality of life (HRQoL) in patients under ...
Fabiane Mateus Siqueira, Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Roberto Pontarolo   +3 more
doaj   +1 more source

HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors [PDF]

, 2014
Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide and probable long-term presence in human population, HCV showed a high degree of inter- and intra-subtype genetic variability. Protease inhibitors (PIs), a
CRAXI, Antonio, DI MARCO, Vito, FERRARO, Donatella, Urone, N   +3 more
core   +1 more source